Ninety One North America’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ninety One North America’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,300	Closed	-$749K	–	125
2016 Q2	$749K	Buy	5,300 +700	+15%	+$103K	0.11%	112
2016 Q1	$601K	Buy	4,600 +1,300	+39%	+$162K	0.1%	110
2015 Q4	$464K	Hold	3,300	–	–	0.08%	106
2015 Q3	$438K	Buy	3,300 +100	+3%	+$17.2K	0.11%	102
2015 Q2	$563K	Hold	3,200	–	–	0.18%	82
2015 Q1	$553K	Sell	3,200 -1,300	-29%	-$223K	0.17%	81
2014 Q4	$737K	Buy	+4,500	New	+$747K	0.22%	73

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ninety One North America's JAZZ Position: Q3 2016 in Review

Ninety One North America sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 5,300 shares — an estimated $749K sold.

Ninety One North America first reported a position in JAZZ in Q4 2014 and held it in 7 quarters. The position peaked at $749K in Q2 2016. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

Ninety One North America reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Ninety One North America sold 5,300 Jazz Pharmaceuticals shares in Q3 2016, an estimated $749K.
Ninety One North America first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 7 quarters.
Ninety One North America's Jazz Pharmaceuticals position peaked at $749K in Q2 2016.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Ninety One North America's 13F filing for Q3 2016, filed 14 Nov 2016.